A Double-Blind, Randomized Study to Compare Onabutuliumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain

Trial Profile

A Double-Blind, Randomized Study to Compare Onabutuliumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary) ; Triamcinolone
  • Indications Pelvic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 20 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 02 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top